Breakthrough & progress of novel targeted lipid-lowering drugs, are you ready?

PCSK9 siRNA drugs focusing on lowering cholesterol
Antisense nucleic acid drugs focusing on reducing triglycerides
Monoclonal antibody drugs lowering both cholesterol and triglycerides
Antisense nucleic acid drugs and siRNA drugs that mainly reduce lipoproteins
An innovative biotech roadshow

Event details

DATE
Wednesday, Mar 13, 2024

VENUE
Online Webex / Zoom

TIME
9:00 – 10:00 Berlin time (CET)
16:00 – 17:00 Beijing time (GMT+8)

RSVP
This is a complimentary event
VIP tickets priority for Lingmed current clients
Please RSVP by Mar 12, 2024

PRESENTERS
Lingling Cao, CEO & Founder
Zhang Ran, Medical advisor

REGISTER
+86 21 5386 3003
BD@lingmed.net

Agenda

CET 9:00 - 9:30	Breakthrough & progress of novel targeted lipid-lowering drugs	by Zhang Ran (Chinese)
CET 9:30 - 9:35	Linkedbio services & projects introduction	by Lingling Cao (English)
CET 9:35 - 9:55	An innovative biotech roadshow	by Guest speaker (English)
CET 9:55 – 10:00	Q&A	(English & Chinese)

Presenters

Zhang Ran
Medical advisor
China Pharmaceutical University master
HealthShare Management and Consulting Co., Ltd Co-founder
20 years of experience in new drug development. Engaged in new drug research and development in Yangtze River Pharmaceutical Group、Beijing Kawin Technology Share-Holding Co., Ltd.、Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.
Co-founded HealthShare in 2016. Serve a number of listed pharmaceutical enterprises. Mainly engaged in research and development pipeline strategic planning, new drug project evaluation, research and development management.

Lingling Cao
CEO & Founder
Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany